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Abstract
Background: Previous reports on patients with radiofrequency catheter ablation (RFCA) of accessory 
pathway (AP) and atrial fibrillation (AF) include only short follow-up periods. The aim of this study 
was to analyze predictors of recurrence of AF in patients after successful RFCA of APs over long term 
follow-up periods.
Methods: Of the 1,007 patients who underwent non-pharmacological treatment of APs (between the 
years 1993–2008),  data of 100 consecutive patients were retrospectively analyzed (75 men, mean age 
43.6 ± 14.7), with the longest period of follow-up (mean 11.3 ± 3.5 years) after successful RFCA of 
AP. In Group 1, there were 72 patients (54 men, mean age 40.66 ± 13.85 years) without documented 
episodes of AF after RFCA of AP. Group 2 consisted of 28 patients (21 men, mean age 50.79 ± 14.49 
years) with AF episodes despite successful elimination of AP.
Results: In univariate analysis, patients from Group 1 were significantly younger at the time of abla-
tion than patients from Group 2 (40.66 ± 13.85 vs. 50.79 ± 14.49 years; p = 0.002), had shorter his-
tory of AF episodes (4.11 ± 4.07 vs. 8.25 ± 7.50 years; p = 0.024) and had less frequently documented 
atrial tachycardia (AT) prior to ablation (3.39 vs. 20.00%; p = 0.022). In multivariate analysis, the 
history of AF in years (p = 0.043), was an independent risk factor for AF recurrences.
Conclusions: Older patient age, longer history of AF and AT prior to RFCA of APs identified a sub-
group of patients who required additional treatment. In the multivariate analysis, the history of AF in 
years (p = 0.043) was a risk factor for AF recurrence. (Cardiol J 2017; 24, 6: 597–603)
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Introduction
Pre-excitation occurs in 0.1–0.3% of the gen-
eral population [1–5]. Among patients with ac-
cessory pathways (APs), the incidence of atrial 
fibrillation (AF) has been reported to be as high as 
30%, which is far greater than the incidence of AF 
in the general population where it is 3–4% [6, 7]. 
Such a high occurrence of AF in patients with 
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pre-excitation are at risk of sudden cardiac death 
(SCD). The generally accepted mechanism for SCD 
in Wolff-Parkinson-White syndrome (WPW) is the fast 
conduction of AF to the ventricles over an AP with 
subsequent degeneration into ventricular fibrillation 
(VF) [9–11]. The current guidelines recommend 
radiofrequency catheter ablation (RFCA) as the first 
line therapy in patients having AF and WPW [12–14]. 
Research has demonstrated that following 
successful surgical dissection of APs, there is an 
almost complete elimination of paroxysmal AF; 
however, the patients in these studies were young 
[15–17]. Less information exists concerning RFCA 
due to the enrollment of small groups of patients in 
previous studies and a short follow-up period [18–20].
Among patients with WPW and AF, ablation of 
AP may have a sufficient clinical impact of prevent-
ing recurrence of AF in selected patients [21]. Some 
patients need additional attention and treatment [19].
The aim of this study was to analyze the predic-
tors of recurrence of AF in patients after successful 
RFCA of AP during long term follow-up and ascer-
tain the impact of ablation on future AF risk [18, 19].
Methods
Study patients
Of the 1,007 patients (mean age 35.00 ± 15; 
45% female) who underwent non-pharmacological 
treatment of APs (years 1993–2008), 281 patients 
(28%) had AF (Fig. 1). 
Data were retrospectively analyzed for 100 
consecutive patients (75 male, 25 female, mean age 
43.6 ± 14.7 years, range 15–74), with the longest 
period of follow-up (mean 11.3 ± 3.5 years) after 
successful RFCA of AP in order to accomplish the 
longest follow-up ever published on a large group of 
patients. This was a retrospective analysis, never-
theless the follow-up was prospectively designed. 
 Patients with persistent AF prior to ablation 
were excluded and patients with a history of VF 
were the topic of a previous publication [22]. 
Clinical, electrocardiographic, electrophysio l-
ogical, and echocardiographic data were analyzed.
Ethics
The study was conducted according to the 
Declaration of Helsinki. All patients provided writ-
ten, informed consent for the ablation procedure 
and for the scientific data analysis. The consent for 
the procedure was approved by the Institutional 
Ethics Committee.
Electrophysiological study
In patients with a history of AF, the aim of 
the electrophysiological study was to confirm the 
diagnosis and to perform the ablation procedure 
as safely as possible. Aggressive atrial stimula-
Figure 1. Inadvertently induced ventricular fibrillation by non-synchronized cardioversion of atrial fibrillation con-
ducted by the accessory pathway.
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tion was therefore avoided in order to reduce the 
risk of inducing life-threatening arrhythmia. As 
amiodarone was administered prior to admission 
to this institution in most patients after a VF or AF 
episode with fast ventricular response, the refrac-
tory periods of AP and AV node were not analyzed.
Statistical analysis
Continuous variables were expressed as means 
and standard deviations (SD). The Yates-corrected c2 
test was used to compare fractions of two categorical 
variables and the maximum-likelihood c2 test was 
used when larger frequency tables were constructed. 
The differences in the means of continuous variables 
were investigated with t-test and analysis of variance 
(ANOVA). Post-hoc comparisons in the analysis of 
variance were made with Tukey’s range test. The 
Pearson correlation was used to investigate relation-
ships between two continuous variables. P < 0.05 
was considered statistically significant.
Definitions
The location of the AP was retrospectively 
described using the anatomic nomenclature pro-
posed by the European Society of Cardiology and 
the North American Society of Pacing and Elec-
trophysiology [23].
Accessory pathways were grouped into three 
locations: left free wall (left superior, left poste-
riorsuperior, left posterior, left posteroinferior 
and left inferior), septal-paraseptal region (su-
peroparaseptal, septal and inferoparaseptal), and 
right free wall (right superior, right superoante-
rior, right anterior, right anteroinferior and right 
inferior) [24].
Multiple APs (or an AP with multiple ven-
tricular or atrial insertions, Fig. 2) was defined as 
previously described [25].
Follow-up
Patients underwent routine follow-up at 
6 and 12 months after ablation in the outpatient 
clinic of the hospital or by the referring physician. 
Echocardiography was performed on all patients 
and they had undergone two or more Holter elec-
trocardiogram (ECG) recordings. After 12 months, 
patients with no palpitation and no pre-excitation in 
ECG were referred to regional outpatient cardio-
vascular centers. There a Holter ECG recordings 
were performed at least once a year.
Late follow-up after a mean of 11.3 ± 3.5 years 
was performed by questionnaire designed by the 
authors or by direct telephone interviews with 
patients and/or via direct contact with the referring 
physician. During late follow-up, 73% of patients 
were still under cardiac supervision in a regional 
outpatient clinic. When patients had documented 
arrhythmias during the follow-up period, informa-
Figure 2. Atrial fibrillation with changing pre-excitation induced by pacing from right ventricle in patient with history 
of ventricular fibrillation episode, multiple accessory pathways and Ebstein anomaly. Following evolutions: QRS 2, 7 
— inferoparaseptal pathway (QRS 150 ms), QRS 3, 4, 6 — right antero-superior pathway (QRS 190 ms). 
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tion regarding these arrhythmias were obtained 
from the referring physicians and documentation 
was sought. The methodology of late follow-up 
contact was published previously [19].
Results
In Group 1, there were 72 patients (54 males, 
18 females; mean age: 40.66 ± 13.85 years) with-
out documented episodes of AF after RFCA of 
AP. Group 2 consisted of 28 patients (21 males, 
7 females; mean age: 50.79 ± 14.49 years) with AF 
episodes despite the successful elimination of AP. 
119 RFCA of APs in 100 patients were performed 
(range 1–5, mean 1.2).
Clinical data
Clinical data are presented in Table 1. Using 
univariate analysis, patients from Group 1 were 
found to be significantly younger, at the time 
of ablation, than were patients from Group 2: 
40.66 ± 13.85 vs. 50.79 ± 14.49 years (p = 0.002), 
respectively. Furthermore, patients from Group 1 
had a shorter history of AF episodes: 4.11 ± 4.07 
vs. 8.25 ± 7.50 years (p = 0.024), respectively.
Electrocardiographic  
and electrophysiological data
Data are presented in Table 2. In Group 1, 
there were significantly less patients with docu-
mented atrial tachycardia (AT) prior to ablation 
3.39 vs. 20.00 (p = 0.022), respectively.
Echocardiographic data
Echocardiographic assessment was performed 
in all patients from both groups (Table 3).
Deaths during follow-up
During follow-up, 2 patients died despite suc-
cessful RFCA of AP. Both had a normal ejection 
fraction as well as hypertension and dyslipidemia. 
The first patient died at the age of 69, due to cancer 
9 years after RFCA of AP. According to the family, 
the second patient died at age of 71, 6 months after 
RFCA, due to respiratory failure.
Multivariate analysis
Using multivariate analysis, only a history of 
AF in years (p = 0.043) were independent risk 
factors for AF recurrences.
Discussion
The present study investigated AF recurrence 
in one of the largest cohorts of patients with par-
oxysmal AF and RFCA of APs. It was sought to 
describe the long-term outcomes of AP and AF 
patients and ascertain the impact of ablation on 
future AF risk.
Data of patients with AF and RFCA of APs 
published previously reported a relatively short 
follow-up that lasted from 23.9 ± 12 to 35 ± 12 
months [18, 19]. Research herein indicates that the 
present study has the longest follow-up period of 
11 years. This study demonstrates that a shorter 
Table 1. Clinical data.
Group 1 Group 2 P
Age during ablation [years] 40.66 ± 13.85 50.79 ± 14.49 0.002
History of AF [years] 4.11 ± 4.07 8.25 ± 7.50 0.024
History of AVRT [years] 17.26 ± 11.85 24.25 ± 12.55 NS
Follow-up [years] 11.24 ± 3.20 11.82 ± 4.29 NS
Age during 1 episode of AF [years] 37.67 ± 14.71 40.35 ± 14.68 NS
Age during 1 episode of AVRT [years] 21.81 ± 13.49 25.64 ± 18.94 NS
Male gender [%] 75.00 75.00 NS
Body mass index 25.73 ± 3.41 26.72 ± 3.32 NS
Hypertension [%] 25.81 33.33 NS
Dyslipidemia [%] 43.0 46.66 NS
Diabetes [%] 5.26 8.70 NS
Heart failure [%] 0.0 0.0 NS
AF — atrial fibrillation; AVRT — atrioventricular reentrant tachycardia; NS — not significant
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period between the diagnosis of AF in patients 
with APs to the treatment and elimination of APs 
reduces the risk of future AF episodes. This is also 
observed in patients without AP [26]. The present 
research finds that this correlation has not yet been 
reported for AP and AF patients. 
Moreover, one of the most important findings of 
this study is that patients with AF recurrence after 
the elimination of APs is more commonly docu-
mented in AT prior to ablation. Miyamoto et al. [20] 
reported a correlation of premature atrial com-
plexes prior to ablation of atrioventricular nodal re-
ciprocating tachycardia (AVNRT) or AP and higher 
recurrences of AF after a successful procedure.
More frequently documented episodes of AT 
in patients with AF after RFCA of AP in these 
patients, may suggest that, in Group 2, there were 
more patients with focal AF, triggers in pulmonary 
veins, or focal re-entry of electrical signal propaga-
tion in the left atrium [13].
Table 2. Electrocardiographic and electrophysiological data.
Group 1 Group 2 P
Documented AT [%] 3.39 20.00 0.022
Overt pre-excitation [%] 83.33 71.43 NS
Intermittent pre-excitation [%] 6.94 10.71 NS
Concealed AP [%] 9.73 17.86 NS
Documented AVRT [%] 79.17 67.86 NS
Documented AVNRT [%] 2.94 8.70 NS
Documented AF [%] 9.43 10.00 NS
Documented VF [%] 1.41 3.57 NS
Mean SPRR [ms] 250.00 ± 67.85 274.62 ± 100.88 NS
Mean max. AVRT [bpm] 220.77 ± 41.59 208.13 ± 28.10 NS
Mean min. AVRT [bpm] 182.32 ± 27.13 178.57 ± 26.85 NS
RFW [%] 12.50 21.43 NS
LFW [%] 61.12 50.00 NS
Midseptal/posteroseptal [%] 26.38 28.57 NS
MAP [%] 22.86 25.00 NS
ECV [%] 43.18 45.45 NS
AF — atrial fibrillation; AP — accessory pathway; AT — atrial tachycardia; AVNRT — atrioventricular nodal reciprocating tachycardia;  
AVRT — atrioventricular reciprocating tachycardia; ECV — electrical cardioversion; LFW — left free wall; MAP — multiple accessory pathways; 
NS — not significant; mean SPRR — mean shortest pre-excited RR; RFW — right free wall; VF — ventricular fibrillation
Table 3. Echocardiographic data.
Group 1 Group 2 P
Ejection fraction [%] 66.40 ± 7.58 65.29 ± 5.97 NS
Shortening fraction [%] 37.88 ± 6.41 36.29 ± 4.69 NS
LA [cm] 3.68 ± 0.55 3.74 ± 0.57 NS
LVDD [cm] 4.97 ± 0.38 5.03 ± 0.44 NS
LVSD [cm] 3.15 ± 0.53 3.17 ± 0.34 NS
LVEDV [mL] 115.91 ± 29.02 121.39 ± 25.34 NS
LVESV [mL] 41.05 ± 13.99 39.79 ± 9.62 NS
Stroke volume [mL] 76.18 ± 19.97 80.14 ± 19.31 NS
IVSD [cm] 1.07 ± 0.13 1.07 ± 0.15 NS
Additional heart diseases [%] 8.06 10.00 NS
IVSD — interventricular septal diameter; LA — left atrium; LVDD — left ventricular diastolic diameter; LVSD — left ventricular systolic diameter; 
LVEDV — left ventricular end-diastolic volume; LVESV — left ventricular end-systolic volume; NS — not significant
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These findings support the observations of 
Dagres et al. [19], which indicated that age is a risk 
factor for AF recurrence. Patients with recurrences 
of AF several years after elimination of AP, prob-
ably revealed a second mechanism of AF episodes, 
which is not connected with AP.
Limitations of the study
Data were collected on ablation procedures, 
retrospectively. However, long-term follow-up was 
prospectively designed. It is not possible to refute 
the theory that some patients from Group 1 were 
asymptomatic of or did not report experiencing AF.
Conclusions
Older patient age, longer history of AF, and the 
presence of AT episodes prior to RFCA of APs in 
patients with an AP and AF indicated the need for 
additional treatment. Upon multivariate analysis, 
only a history of AF (p = 0.043) was an independ-
ent risk factor for AF recurrence.
This data may assist physicians to advise 
patients properly regarding the future risk of ar-
rhythmia as well as anticoagulation.
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